ImmuPharma (LON:IMM) Stock Price Up 12.8% – Here’s What Happened

ImmuPharma plc (LON:IMM) shares were up 12.8% during trading on Thursday . The company traded as high as GBX 1.70 ($0.02) and last traded at GBX 1.70 ($0.02). Approximately 951,330 shares changed hands during trading, a decline of 84% from the average daily volume of 6,000,400 shares. The stock had previously closed at GBX 1.50 ($0.02).

ImmuPharma Price Performance

The stock has a 50-day moving average price of GBX 2.07 and a 200 day moving average price of GBX 2.81. The firm has a market cap of £7.12 million, a price-to-earnings ratio of -2.90 and a beta of 1.53.

ImmuPharma (LON:IMM) last posted its earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, equities research analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.